The 2023 STAT Summit is only TWO weeks away
Dear STAT reader,
It hasn't been an easy year for biotech companies. The Nasdaq biotechnology index is slightly down for the year, and the IPO window is still closed.
Biotech executives, researchers, and entrepreneurs are a key part of our audience here at STAT. That's why at the STAT Summit, our biggest event of the year, we'll be taking a hard look at how to build biotechnology companies even in a tough environment.
We'll have Adam Feuerstein, the dean of biotech muckraking, talking to a panel of CEOs who most definitely made it during the downturn. That will include Vlad Coric, the CEO of BioHaven, which saw its previous incarnation bought by Pfizer for $11.6 billion, and Athena Contouriotis, who ran Turning Point Therapeutics, which was sold to Bristol Myers Squibb for $4.1 billion.
STAT's Alison DeAngelis will interview John Maragnore, who, in his "retirement," has become a major force in venture capital. They'll probably talk a little bit about how he built Alnylam into a powerhouse, too. We'll also have a fireside with Flagship founder and CEO Noubar Afeyan, who started Moderna, among other companies. He and I may debate what "biology's century" really means.
And no company has had a more dramatic range of ups and downs than Biogen. I'll interview CEO Christopher Viehbacher about his first year on the job.
Those are just a few of the speakers at our big event. Others will include the CEOs of GSK and the Dana Farber Cancer Institute, health equity researchers Harlan Krumholz of Yale, Monica McLemore of the University of Washington, and Monica Peek, of the University of Chicago. We'll also have two virtual sessions, one with Michael J. Fox and Debi Brooks of the Michael J. Fox Foundation and another with Mark Zuckerberg and Priscilla Chan of the Chan Zuckerberg Initiative.
JOIN US
I promise that you'll learn a lot, have the chance to ask your own questions, and get to hang out with a crowd of amazing people.
Best,
Matthew Herper
No comments